Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;17(4):356-363.
doi: 10.1159/000522198. Epub 2022 Jan 27.

Clinical Outcomes in Breast Cancer Patients with HER2-Positive, Node-Negative Tumors (≤3 cm)

Naoko Iwamoto  1 , Tomoyuki Aruga  1 , Shinichiro Horiguchi  2
Affiliations

Clinical Outcomes in Breast Cancer Patients with HER2-Positive, Node-Negative Tumors (≤3 cm)

Naoko Iwamoto et al. Breast Care (Basel). 2022 Aug.
No abstract available

Keywords: Adjuvant therapy; Small tumor; Trastuzumab.

PubMed Disclaimer

Conflict of interest statement

T. Aruga has received honoraria from Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., and Pfizer Japan Inc. N. Iwamoto has no conflict of interest to declare.

Figures

Fig. 1
Fig. 1
Patient enrollment flow. BC, breast cancer; NAC, neoadjuvant chemotherapy; CT, chemotherapy.
Fig. 2
Fig. 2
Distant disease-free survival (D-DFS) according to pT stage.
Fig. 3
Fig. 3
Disease-free survival (DFS) according to pT stage.
Fig. 4
Fig. 4
Overall survival (OS) according to pT stage.
See this image and copyright information in PMC

References

    1. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2018;20:3744–52. - PMC - PubMed
    1. Gingras I, Holmes E, Azambuja ED, et al. Regional nodal irradiation after breast conserving surgery for early HER2-positive breast cancer: results of a subanalysis from the ALTTO trial. J Natl Cancer Inst. 2017;109:djw331. - PMC - PubMed
    1. Fehrenbacher L, Capra AM, Quesenberry CP, Jr, et al. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol. 2014;32:2151–8. - PubMed
    1. Horio A, Fujita T, Hayashi H, et al. High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers. Int J Clin Oncol. 2012;17:131–6. - PubMed
    1. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372:134–41. - PMC - PubMed